Published in final edited form as:

Pacing Clin Electrophysiol. 2016 May ; 39(5): 458–470. doi:10.1111/pace.12820.

Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients (PAM-ICD): Rationale and Design of an RCT Currently Underway

Eva R. Serber, Ph.D.¹, Joseph. L Fava, Ph.D.², Lillian M. Christon, Ph.D.¹, Alfred E. Buxton, M.D.³, Jeffrey J. Goldberger, M.D.⁴, Michael R. Gold, M.D., Ph.D.¹, James R. Rodrigue, Ph.D.³, and Michael B. Frisch, Ph.D.⁵

¹Medical University of South Carolina, Charleston, SC

²Centers for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, RI

³Beth Israel Deaconess Medical Center and Harvard University, Boston, MA

⁴Northwestern University, Chicago, IL

⁵Baylor University, Waco, TX

Abstract

Background—Improving mental and physical health of patients with implantable cardioverter defibrillators (ICD) is critical because this group is at high risk for ventricular arrhythmias and sudden death and depressed or anxious CVD patients appear to be at even higher risk for mortality compared to non-depressed or non-anxious CVD patients. Further, autonomic dysfunction is present in these patients, and negative emotions and arrhythmias form a downward spiral further worsening mood, well-being, and cardiovascular health. Much research demonstrates that positive emotion is related to health benefits, improved physiology, and increased survival.

Methods and Results—This is a 2-arm randomized controlled trial aiming to recruit 60 adult ICD patients comparing 12 individually-delivered, weekly sessions of: (1) a positive emotion-focused cognitive-behavioral therapy (Quality of Life Therapy [QOLT]), and (2) Heart Healthy Education. Autonomic functioning, heart rhythm indices, and psychosocial health are measured at baseline, 3- and 9-months. The first goal is feasibility and acceptability, with the primary outcome being arrhythmic event frequency data.

Conclusion—This study is designed to test whether QOLT produces changes in mood, quality of life/wellbeing, autonomic function, and arrhythmic and ICD therapy event rates. This feasibility trial is a foundational step for the next trial of QOLT to help determine whether a 3-month QOLT trial can reduce arrhythmias occurrences among ICD patients, and examine a mechanism of autonomic functioning. This study may help to develop and implement new medical or psychological therapies for ICD patients.

Corresponding Author: Eva R. Serber, PhD; MUSC; Psychiatry, Division of Bio-Behavioral Medicine; 67 President Street, MSC 861; Charleston, SC 29425. FAX: 843-792-4137; Telephone: 843-792-0686; serbere@muscedu.

Conflicts of Interest: none

Clinical Trial Registration: ClinicalTrials.gov (Identifier: NCT02088619)

Keywords

Implantable cardioverter defibrillator (ICD); autonomic function; quality of life; positive emotion; behavioral medicine; psychological treatment

Approximately 50% of all cardiovascular disease deaths are sudden and unexpected. The incidence of sudden death in the United States ranges from 200,000 to 450,000 annually.¹ The implantable cardioverter defibrillator (ICD) is used in patients at risk for ventricular arrhythmias and sudden death. Implant rates have increased ten-fold 1990–2008^{1,2}; with the most recent 2013 estimate of monthly implant rate at 12,500 per month³. Many ICD patients experience depression and anxiety (up to 63% experience anxiety, and 41% experience depression⁴), and reduced quality of life (QOL).^{5,6}

Mental stress and negative emotions can provoke ischemia, arrhythmias, and sudden death among patients with coronary artery disease (CAD), ventricular fibrillation (VF), atrial fibrillation, congestive heart failure (CHF), and ICDs.^{7–19} By contrast, positive emotions and well-being have been shown to: (a) protect against risk of coronary heart disease (CHD);^{20–22} (b) be inversely related to cardiovascular death^{22,23} and mortality;^{22,24} (c) promote recovery and reduce re-hospitalization;^{25–28} (d) improve mental health and social functioning among ICD patients.²⁹

Positive emotion is also associated with several physiological pathways and biomarkers of CVD, such as: cortisol and the HPA axis; blood pressure, heart rate and hemodynamic response; and markers of the inflammatory processes.³⁰ Up to 20% of life-threatening arrhythmias or sudden death are precipitated by an intense emotion, positive or negative in nature (e.g., earthquake, sporting event, World Trade Center Attack),^{11,30,31} an effect replicated in ICD patients after controlling for traditional arrhythmic risk factors and medications.^{9,10} In a recent study examining positivity and heart functioning, happiness was associated with a 40% reduction in the odds of a 24-hour risk of life-threatening arrhythmic events in patients with Long QT Syndrome, with stress having an opposite effect.¹⁷ This is one of the first investigations to indicate the protective effect that positive emotion may have on arrhythmias. The fact that this is one of the first also highlights that the bulk of research on emotion and heart function is still focused on the role of *negative* emotion/distress rather than the *positive* spectrum of the emotional experience.

Several studies have demonstrated associations between emotion and autonomic function, arrhythmias, and cardiac events;^{7–9,15–19} however, thus far studies have not yet demonstrated the mechanism by which emotion and arrhythmias are connected. Autonomic function is one mechanism that is hypothesized to link emotion to arrhythmias. Markers of diminished parasympathetic activity are associated with both ventricular arrhythmias and sudden death, and with depression and anxiety.^{5,6,9,10,15,16,32–34} Patients with ICDs are particularly susceptible to emotion-triggered arrhythmias, sudden death and ICD shocks.^{11,30,31} Thus, ICD patients may directly benefit from a treatment that improves mood, autonomic functioning, and arrhythmias.

Cognitive behavior therapy (CBT), which focuses on symptom reduction of negative emotions, has been the standard for non-pharmacologic treatment of depression and anxiety disorders. CBT has improved depression symptoms and autonomic functioning in ICD patients, but has not reduced the frequency of arrhythmias^{35–38} or ICD shock. However, these studies did not examine shock burden, only time to first shock.^{37,38} A limitation of focusing on shock as an outcome is the relative rarity of the event, and the lack of understanding of the mechanism by which arrhythmia-requiring shock to terminate occurs. Reducing frequency of arrhythmias has greater clinical implications for health than delaying the time to first shock. Furthermore, these previous CBT studies may have been too narrowly focused on the reduction of negative emotions. Studies indicate that positive emotion may influence autonomic function by heightened parasympathetic activity and accelerating cardiovascular recovery following a negative emotion or stressor.^{20,24,25,29,39–44}

Quality of Life Therapy (QOLT) combines CBT and positive psychology techniques and has been empirically validated to improve positive emotion, QOL, and to reduce negative emotion.^{45–48} A paradigm shift toward enhancing positive emotions may provide a beneficial effect on reducing arrhythmia burden.

Study Objectives

The purpose of this article is to present the Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients (PAM-ICD) trial, a clinical randomized controlled trial (RCT) which was designed to test the feasibility and acceptability of a non-pharmacological QOLT intervention among a sample of cardiac patients with ICDs. The PAM-ICD trial is currently funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health (R34 HL107733). This paper discusses the design of the PAM-ICD RCT trial, discussing the research strategy in detail. The aims of the PAM-ICD Trial subscribe to the R34 mechanism – piloting a project with a plan for an R01 study. The study aims are to:

1. examine the feasibility and acceptability of a 3-month positive-emotion focused therapy (QOLT)⁴⁶ modified for ICD patients.
2. obtain estimates of effect size for QOLT compared to a contact-control group (Heart Healthy Education [HHE]) on the changes in arrhythmia frequency and biomarkers of autonomic function, across time (baseline, 3-, and 9-months).
3. obtain estimates of effect size for QOLT compared to a contact-control group (Heart Healthy Education [HHE]) on the changes in emotion, mood, and well-being and QOL, across time (baseline, 3-, and 9-months).

Method

Study Design

The PAM-ICD Trial is a two-group, RCT design (planned $N = 60$ ICD patients; 30 per group) comparing two, 12-week, individually-delivered interventions: (1) “experimental” intervention (QOLT); and (2) “control” group utilizing a contact-control, Heart Healthy

Education (HHE) intervention. Assessments are conducted at baseline, end of intervention (week 12), and at 9 months (6 months, post-intervention completion).

The design was chosen as the best method for answering the questions central to the study. The contact control group was chosen because it will: 1) allow us to control for the amount of contact and attention given to all participants; 2) enable all the participants to receive some benefit from the study; 3) limit attrition and differential dropout rates because all participants will be engaged throughout the study; 4) provide improvement to previous studies' methodological weakness. In addition, it attempts to equalize subject burden between conditions, reducing chance of differential dropout.

All study procedures were approved by the MUSC's Institutional Review Board (Protocol #: Pro00028869), and NHLBI. The study is registered at ClinicalTrials.gov (Identifier: NCT02088619). The study is currently in the recruitment phase.

Sample Size and Power Calculations

While a primary aim of this application is feasibility and acceptability of QOLT, a second important aim is to obtain an estimate of the effect size of a 3-month QOLT intervention on the event rate change in the frequencies of ventricular arrhythmia episodes, that will serve as the basis for a future adequately-powered R01 RCT. Published studies of CBT interventions among ICD patients have not previously examined the effect on arrhythmia frequency, but have examined shock frequency,^{37,38} with one underway examining time to first shock.⁴⁹ Published findings to date are all underpowered.⁵⁰ However, there have been several clinical trials examining ICD programming that have measured the incidence of ventricular arrhythmia episodes, including the PainFREE Rx I trial,⁵¹ which measured 1100 episodes over 12 months in 220 study participants. Several other studies^{52,53} have also measured similar but variant forms of arrhythmias in other populations. Our study population of interest shares many characteristics of the sample within the Wathen⁵¹ study, and we used those frequency counts as the basis for our power and sample size estimation.

While the actual event rate reduction from the QOLT intervention is a focus of this study, our goal is to achieve a 20% reduction in rates, which would likely be clinically significant (Personal Communication, JJ Goldberger, 05/02/2010; AE Buxton, 05/10/2010) in the number of arrhythmia episodes in the QOLT group versus the HHE group. Based on our total sample of 60 (30 in each group), our power to detect significance at this clinically significant 20% reduction will be very low (17% power for a 2-tailed test at $\alpha=.05$). However, if we can achieve that level of reduction in a future R01 with a follow-up period of 2 years, and assuming a 20% attrition rate, we would be able to achieve 80% power for a 2-tailed test at $\alpha=.05$ with an initial sample before attrition of approximately 160 participants. With 60 participants, if we were to achieve a large (50%) reduction in ventricular arrhythmia episodes, we would also achieve 80% power for a 2-tailed test at $\alpha=.05$. *A major study aim in this R34 is to provide a valid effect size estimate of our innovative intervention.*

Study Procedures

Participant Selection, Recruitment, and Randomization—Patients receiving specialized ICD care at the academic medical center are being recruited for the study through the cardiology and electrophysiology clinics. Potential participants will be identified by: 1) the patient's institutional health care providers; and/or 2) attendance to regularly scheduled clinic appointments. Currently, ICD patients do not receive routine psychosocial or psychotherapeutic treatment as part of their standard care at MUSC. We will aim to recruit at least 50% women and 25% minorities.

Patients are *eligible for inclusion* in the study if they meet the following inclusion criteria: (1) adult men and women (≥ 18 years of age) who have received an ICD for primary or secondary prevention of SCD. All patients will have systolic left ventricular dysfunction due to coronary disease or non-ischemic cardiomyopathy. There is no requirement for time since implant. (2) Scoring ≥ 5 on the Hospital Anxiety and Depression Scale (HADS)⁵⁴ on either the anxiety or depression scale. (3) Patients will be able to read and write English and (4) commit to the 3-month QOLT/HHE program and 3 assessments over a 9-month duration.

Patients are *ineligible for participation* if any of the following exclusion criteria: (1) >5% atrial or ventricular pacing; (2) sinus node dysfunction; (3) persistent and permanent atrial fibrillation (history of paroxysmal AF will be allowed); (4) Long QT syndrome; and other channelopathies (e.g., Brugada syndrome, WPW); (5) Hypertrophic cardiomyopathy; (6) Neurocognitive or cognitive impairments based on observation and/or difficulty with informed consent; (7) severe psychopathology that warrants intensive treatment, documented in medical record, by provider, or observed upon screening and consent processes; (8) participation in another research trial; (9) currently being enrolled in psychological or psychiatric treatment (counseling, therapy, etc.). (10) Current psychotropic and cardiac medication prescriptions and usage need to be stable (i.e., no change in type or dosage) for 3-months prior to study enrollment. Medications will be continuously monitored, since cardiac and psychotropic medications can influence autonomic tone. While not initially or formally identified as an exclusion criteria, patients on antiarrhythmic medications, as well as, patients with ventricular assist devices (VAD) or those who are likely to receive a VAD or heart transplant in the next 9 months (duration of study participation) will be excluded. Our center is VAD Center of Excellence (COE), and therefore, while not considered initially in establishing eligibility criteria, this situation has come up. Due to not being able to measure HRV, they are excluded.

Recruitment: Inclusion and exclusion criteria and potential participant's medical history are extensively reviewed by the multidisciplinary research team (psychology, cardiology). During recruitment, a member of the research team will explain the study, assess interest, and conduct a brief screen for eligibility, specifically related to the psychological and medical eligibility criteria (e.g., psychopathology, medications, cardiac diagnoses). As part of the inclusion criteria the patient will need to score ≥ 5 on the HADS on either the depression scale or the anxiety scale, which is a self-report survey completed at screening. Scores of at least 5 on either scale express a level of symptoms that likely impair some area of functioning.^{55–59} The requirement of symptoms of anxiety or depression for inclusion

into the study is to enable improvement in mood and autonomic function. Therapy cannot be expected to enhance mood and well-being if participants are already feeling good. Additionally since negative mood is related to autonomic dysfunction, full effect of the intervention is again not possible if participants are starting the intervention physically and/or mentally healthy. If eligible for the study, written informed consent and HIPAA authorization are obtained from the participant and baseline assessment scheduled. Included in consent is permission for the research team to contact their general practitioner and/or cardiologist regarding medication, general health status, and provide information about the study. The investigator will communicate extensively with the patient's cardiologist to seek reinforcement regarding the benefits of patient participation.

Intervention commencement initially was not to begin until after a series of individualized prerequisites were met; however, due to slow recruitment and difficulties participants were having arriving at appointments (e.g., due to significant travel distances), we have changed the flow minimally. Originally planned as a) screening, b) informed consent, c) baseline assessment, d) randomization, e) first intervention session; as separate steps; steps b-e have now been combined into one visit. Baseline assessment remains in two parts; and thus, randomization and first intervention session are combined into the second part of the assessment (upon the return of Holter monitor and questionnaires). Since this change, we have seen positive response from participants and a reduction in attrition from baseline assessment to start of intervention.

Randomization: Participants are randomized to one of two treatment groups, stratified by indication for ICD (primary vs. secondary prevention), and age ($<$ or $\geq$ 65 years old). We assume that most patients will be taking a beta-blocker, which will be controlled using statistical procedures rather than stratifying during randomization, along with time since implant.

Overview of the Intervention

Both of the treatment conditions are 12 sessions and are delivered as individual therapy. The goal is 45–60 minute sessions for both groups, and for sessions to occur weekly. This study is examining feasibility and dosing of treatment, and therefore, accounting for illness and various daily hassles, duration of intervention will be stopped at 18 weeks, regardless of whether participants have completed all 12 sessions. If a participant cannot attend or misses a session, a make-up session is arranged. Sessions were originally planned to be in-person; however, due to our population and catchment area (regional medical center) we have extended to a blend of in-person and phone sessions to facilitate recruitment and retention. Rates of phone and in-person sessions are tracked and compared between intervention groups.

Quality of Life Therapy (QOLT) Intervention—Quality of Life Therapy (QOLT) combines cognitive, behavioral, and positive psychology techniques and has been empirically validated to improve positive emotion, quality of life (QOL), and reduce negative emotion.^{45–48,60} QOLT is considered one of seven empirically validated approaches in the field of positive psychology, and composed of intervention techniques considered

promising in the field of positive psychology.⁴⁷ QOLT treatment has three foci now recognized as the three elements of happiness: 1) increased life satisfaction, 2) increased positive emotion, and 3) reduced negative emotional experience.⁶¹ Key resiliency factors are positive emotion, cognitive flexibility, life meaning, social support, and active coping strategies.⁶² QOLT has been validated among clinically depressed community volunteers,⁶⁰ lung transplant recipients and caregivers,^{45,48} end-stage renal disease awaiting transplant,^{63,64} hepatitis C patients awaiting liver transplantation, and in children with OCD and their mothers.⁶⁵ All of these studies have demonstrated QOLT, in an individually-delivered format, is more effective than supportive therapy or a control group in enhancing mood, QOL, life satisfaction, and reducing negative symptoms.

Participants receive a workbook of content discussed, homework assignments, and worksheets. Each session consists of: (1) review of the previous week's content and homework, (2) didactic content of new material and/or techniques, (3) relaxation exercises, and (4) time for discussion about the new content, homework assignment, and barriers to completion. Participants are taught several cognitive and behavioral techniques for boosting their satisfaction and happiness.

The intervention focuses on QOL areas that are most pertinent to ICD patients. For example, Play (e.g., recreational activities, physical activity) is an area of attention as distressed ICD patients tend to limit pleasurable activities. The area of Relationships also receives attention and significant loved ones will be invited to participate in these sessions. Participants are taught skills for improving self-esteem and other positive emotions – essential happiness beliefs such as learned optimism, finding meaning, the need for self-care and renewal on a daily basis, and service to others. Specific techniques that are taught include relaxation techniques, self-monitoring and cognitive restructuring, activity scheduling, and problem-solving and goal setting. In addition, as in other behavioral interventions for health promotion, QOLT includes a daily habit of health promoting behaviors (e.g., exercise, treatment compliance) and relapse prevention and maintenance of distress.⁶⁶

Heart Healthy Education Contact Control—Serving as a contact control condition, the participants randomized to this intervention match the QOLT intervention in terms of number of sessions. Duration is also attempted to be matched, with sessions ranging from 30–60 minutes (duration of sessions is recorded and will be examined across the two interventions). Each session will include education provided in the form of written materials/handouts, presentations, and/or films (video/DVD), and time for discussion. Content will address a variety of health and lifestyle issues related to cardiovascular health, disease prevention, and progression. Didactic topics may include nutrition, smoking cessation, physical activity, stress management, well-being, social support, and sleep. Sessions do not include any therapeutic techniques or any form of instruction beyond the didactic material for that session.

Participant Retention, Differential Dropout and Follow-up—To reduce likelihood of differential dropout between the two conditions, we have included several features. First, by utilizing a contact control group (HHE), all participants have regular contact with project staff, as well as receiving education materials. Therefore, both groups are receiving

beneficial treatment they might not have if not enrolled in the study. Previous trials conducted by Serber et al (HL092340) and Marcus' et al demonstrate no differential dropout rate between intervention vs. contact control "wellness" groups.^{67,68} Second, participants complete and return baseline psychosocial measures in-person prior to randomization for study participation. After baseline assessment has been completed, participants are provided with information about randomization, the study, and their intervention assignment. These steps increase the likelihood of only randomizing individuals who will comply with the study. Finally, all participants receive frequent telephone, email, and/or mail reminders of upcoming and missed sessions and assessments. "Completers" are defined as those attending at least 75% of the QOLT/HHE sessions over the 3- month period. To maximize adherence, we provide monetary incentives (i.e., gift cards to local popular stores) for their time in completing the assessments and intervention. Retention and attrition are closely recorded for feasibility and acceptability of the intervention and trial design.

Assessment

Participants complete all assessments on the same schedule, irrespective of intervention arm. Assessments are conducted at baseline prior to randomization, 3-months (end of intervention), and 9-months. Assessments include: medical record review including ICD interrogation/device reports, 24-hr Holter monitor recording, interview and a self-report questionnaire packet to collect QOL and psychosocial information. The packet of questionnaires take approximately 30 minutes to complete. A 6-month assessment includes only their ICD interrogation for event rates and the HADS. If at any time, during assessments or intervention, immediate, individual psychological services are warranted (e.g., suicidal ideation, extreme behavior), an appropriate referral will be made. All data for assessments are collected in one session. The 24-hour Holter recorder will be placed by trained hospital staff. Project staff conducting assessments and entering data will be blinded to which intervention participant has been assigned.

Sociodemographic and Medical History Data—These data are collected from patients' medical charts. Medical information includes: current cardiac diagnosis, disease duration, previous CVD and ICD history, past cardiac procedures, comorbid illness, and current medications. We gather baseline measures of cardiac functioning, including left ventricular ejection fraction (LVEF%), systolic and diastolic blood pressure.

Measurement of Ventricular Arrhythmias—Ventricular arrhythmia burden is not often the focus of studies, as shocks have received a majority of the attention since the development of ICDs as they are associated with the most prominent symptoms; however, it is clear that frequency of arrhythmias is an index of deteriorating cardiac health and impairs survival.⁶⁹ Arrhythmias' vs. shock's impact on the heart has yielded inconsistent evidence of which is the contributor to mortality, and while the debate has not been resolved, it is generally accepted that more shocks is synonymous with more arrhythmias, and overall "sicker hearts."⁷⁰⁻⁷² As this debate continues, a common conception is that greater arrhythmia burden is suggestive of greater ICD therapies delivered and higher mortality risk. This study focuses on arrhythmia burden, the beginning of this trajectory, and allows for measurement feasibility in this proposal.

Arrhythmias: Arrhythmia frequencies are collected from: (1) the ICD, and (2) 24-Holter monitor recording at baseline, 3-, and 9-months. The ICD stores a record of the percent of heartbeats that are paced and sensed, and ventricular tachyarrhythmias causing ICD discharge, as well as nonsustained episodes. The ICD is interrogated every 3–6 months in the clinic or via home monitoring; with every attempt for participants to have their ICD interrogated every 3 months (previous standard of care), allowing determination of arrhythmia frequency and ICD therapies. For patients who only have their devices interrogated in clinic (usually every 6 months to 1 year), full and detailed Arrhythmia Logbooks from their devices are obtained at these clinic visits to facilitate examining frequencies of arrhythmias and ICD therapies across the study participation period. ICD detection criteria will be examined and taken into account when examining event data. All participants are treated by one institution's electrophysiologists, and therefore, have general comparability as their practices are similar at the one institution.^{52,73} Although a majority of episodes of VT are brief, asymptomatic and do not warrant treatment themselves, data from the CAST trial indicate that episodes of VT >100 BPM have adverse prognostic significance, and in the absence of antiarrhythmic agents such as flecainide, greater frequency and faster rate do not correlate with increased mortality in post-MI patients.⁷⁴ Data reported from the MUSTT trial of patients with CHD, EF 40%, and spontaneous non-sustained VT indicate that longer episodes (≥ 6 beats) are associated with increased risk of cardiac arrest or sudden death. The mean rate of episodes does not relate to SCD risk but all patients had cycle length <500 msec.

Arrhythmia outcomes will be in the form of a continuous variable of the number of occurrences, whether they occurred in the same episode (same 24-hours) or on different days. Baseline counts will be summed from the previous 3 months prior to commencing the intervention (months –3–0), 3-month data (post-intervention) will sum counts of the three months during the intervention (months 0–3), the 6-month follow-up data will be counts of the previous 3 months (months 3–6). At the 9-month assessment, counts will be of the previous 3 months (months 6–9), and of the past 6 months since the end of the intervention (months 3–9). We will also explore differences in rates of tachycardia (100–149, 150–200, and >200 BPM), but total arrhythmia frequencies will be the sum of NSVT detected on the Holter (≥ 6 beats, at >120 BPM) plus arrhythmias detected by the ICD. We will also analyze arrhythmia characteristics, including morphology (polymorphic vs. uniform).

ICD Therapies: All therapies (ATP, shocks) delivered by the ICD will also be counted in the same manner as arrhythmias. This will serve as an exploratory outcome.

Measurement of Autonomic Function—Autonomic dysfunction is the common element in arrhythmias and negative emotion and mood; and therefore obtaining an effect size for change in autonomic function, specifically HF-HRV, an index of parasympathetic activity; will be the primary interest among HRV variables in this R34. HRV is a widely accepted index of measuring autonomic balance.^{71,72,75} There are a number ways that HRV can be analyzed and no consensus exists as to which method is superior. The JACC review suggests that several methods can be considered complementary to each other.⁷⁶ As noted in the consensus statement of JACC,⁷⁷ HRT is an indirect index of baroreflex sensitivity, and

has been found appropriate in risk stratification after acute myocardial infarction, risk prediction, and monitoring of disease progression in heart failure, as well as in several other pathologies. T-wave Alternans (TWA) appears to be a useful marker of risk for arrhythmias according to the consensus statement of the International Society for Holter and Noninvasive Electrocardiology published in JACC.⁷⁷ TWA has received a great deal of attention for risk stratification of sudden cardiac death and as an arrhythmia marker, particularly in ICD patients. The combination of TWA with HRT taken from ambulatory ECGs is also being examined in a current NHLBI trial, REFINE-ICD (NCT00673842). Both sympathetic and parasympathetic branches of autonomic functioning affect TWA, along with various other cardiovascular measures, underscoring the link between TWA and arrhythmogenesis.⁷⁸

Linear Heart Rate Variability (HRV): Linear and nonlinear HRV and HRT will be measured for best estimates of autonomic function. These will be calculated from data obtained by the 24-Holter recordings and analyses. HRV is an indicator of regulation of the heart by the autonomic nervous system. HRV is commonly analyzed in time and frequency domains. Most time domain indices reflect the overall autonomic modulation of heart rate. The frequency domain method involves power spectral analyses of HRV; the high frequency (HF) components have been shown to be due to parasympathetic modulation (of primary interest) and the low frequency (LF) components have been shown to be due to sympathetic and parasympathetic modulation of the heart rate. HRV analyses will be performed in accordance with the recommendations from the Task Force of the ESC/NASPE,⁷⁹ using the recommended time-domain variables: standard deviation of all normal RR intervals (SDNN), the standard deviation of the average normal RR intervals (SDANN), and root mean square of successive RR interval differences (RMSSD). RMSSD is highly correlated and a stable index of respiratory sinus arrhythmia (RSA).⁸⁰ Heart rate oscillations at HF also reflect RSA and considered a marker of cardiac parasympathetic activity.^{81–83} We will examine HF, LF, and LF/HF ratio.

Heart Rate Turbulence (HRT): HRT describes the biphasic reaction of acceleration and deceleration of the sinus rhythm in response to a premature ventricular beat.⁸⁴ It is an indicator of baroreflex sensitivity. The baroreflex response is believed to reflect the capability of the regulatory system to increase vagal activity in response to changing blood pressure.⁸⁵ HRT will also be collected from a 24-hour Holter monitor based on calculations using an algorithm adapted from the Working Group of Biological Signal Analyses popularizing the non-commercial use of HRT (www.h-r-t.org).⁸⁶ Two numerical descriptors will be estimated: turbulence onset (TO) reflecting the initial phase of sinus rhythm acceleration, and turbulence slope (TS) describing the deceleration phase. TO is the difference between the mean cycle length of the first two beats following the post- premature ventricular contraction pause (R+1, R+2) and the two beats preceding premature ventricular contraction (R–1, R–2) as a percentage of preceding cycle lengths: $TO = 100 * (R+1, R+2) - (R-1, R-2) / (R-1, R-2)$, where $TO < 0\%$ is normal.⁸⁷ TS is the steepest slope of linear regression lines for sequences of five consecutive post-premature ventricular contraction intervals for up to 20 beats. Normal $TS = 2.5 \text{ mm/RR}$.⁸⁷ When using both HRT parameters simultaneously, participants can be classified as having two HRT parameters normal, one parameter abnormal, or two abnormal.⁸⁸

T-wave Alternans (TWA): T-wave alternans (TWA), defined as a beat-to-beat fluctuation in ST-segment or T-wave morphology, has emerged as a useful electrocardiographic (ECG) marker of risk for cardiovascular mortality and SCD. TWA will be obtained from analyzing the 24-hour Holter monitor recordings based on consensus guidelines.⁸⁹

Psychological Well-being Measures—Psychological measures are given at the three assessments to determine whether QOLT has direct effects on improving psychological well-being and QOL from baseline to 3-, and 9- month assessment compared to HHE.

Screening: The Hospital Anxiety and Depression Scale (HADS) is used as a screening measure for eligibility in the study, and is also administered at 6-months after initiating the intervention. It measures depression and anxiety in hospital and outpatient settings, and is particularly useful for medical populations.⁵⁴ The HADS is valid and reliable, and in a variety of populations, including ICD patients.^{58,90} Part of the inclusion criteria is scoring 5 on the HADS on either the depression or the anxiety scale; those scoring at least 5 on either scale are still expressing a level of symptoms that are likely impairing some area of functioning, while still enabling improvement via intervention.^{58,59,91} ICD studies yielded mean HADS subscale scores ($M \pm SD$) $2.24 \pm 2.52 - 5.9 \pm 4.65$, as well as prevalence rates of scores >8 estimated at 25–53% for depression and anxiety, respectively.^{55–57}

Outcome measures: Other psychological outcome measures include ICD-specific, positive and negative emotions and mood, and quality of life. These measures are administered at baseline, 3-months after initiating the intervention, and again at 9-months after initiating the intervention. The Florida Shock Anxiety Scale (FSAS) assesses device-specific fears regarding experiencing a shock, applicable to those who have and have not experienced a shock.⁹² It has a total score and two reliable subscales: consequences of device firing, and triggers of device firing that can be calculated. All scales have good reliability (.74–.91).⁹² The Florida Patient Acceptance Scale (FPAS)⁹³ assesses patient acceptance of the ICD. The FPAS is comprised of four consistent factors: Return to Function, Device-related Distress, Positive Appraisal, and Body Image Concerns. The FPAS demonstrated convergent, divergent, and predictive validity when compared to other self-report measures (e.g., SF-36).⁹³ The Emotions Questionnaire is used to measure happiness.⁹⁴ It provides quantitative and qualitative information about happiness/unhappiness, and according to Diener⁹⁵ provides the most important qualities of well-being (i.e., frequency and intensity of affect). It has established strong validity and reliability.⁹⁴ Other measures include the Center for Epidemiologic Studies – Depression Scale (CES-D)⁹⁶ for depression, the State Trait Anxiety Inventory (STAI)⁹⁷ for state and trait anxiety, the Life Orientation Test – Revised (LOT-R)⁹⁸ for generalized expectancies (dispositional optimism), the Positive and Negative Affect Schedule (PANAS)⁹⁹ for positive and negative emotion, and the Satisfaction with Life Scale (SWLS)¹⁰⁰ for satisfaction with life. The Quality of Life Inventory (QOLI)¹⁰¹ is a domain-based life satisfaction instrument that consists of 16 items of the 16 domains of QOL according to QOLT and with strong reliability and validity.¹⁰¹ Health related QOL will be measured by the Short-Form Health Survey-36 (SF-36)¹⁰² for general health-related QOL, Minnesota Living with Heart Failure Questionnaire (MLHFQ)¹⁰³ for cardiac-specific QOL.

Feasibility, Acceptability, and Treatment Integrity measures—Feasibility will be determined from recruitment and attrition data, and process variables of attendance and homework assignment completion. The latter two, along with treatment satisfaction, will be used as indices of acceptability. Attendance, homework assignment completion, and treatment satisfaction, will be measured on a weekly basis, and at the 3-month assessment. These measures will also serve as an indicator of treatment acceptability. We will also gather self-report data on participant and interventionist satisfaction with the interventions, which will also be used for “acceptability” of the intervention. The Program Evaluation Survey is a project-designed survey that is included in the 3-month assessment asking the participants to evaluate their experience with the intervention in which they participated and includes quantitative and qualitative-descriptive data. Each session, we track whether sessions occurred in person or by phone. The proportion of sessions attended versus sessions required for protocol and homework completion will be used as measures of treatment fidelity. In addition, treatment fidelity is self-rated by each interventionist each session on 1–5 Likert-type scales developed for use in this study (QOLT Fidelity and HHE Fidelity). For treatment fidelity and quality control, all sessions in both conditions will be audio taped and reviewed on a regular basis. There were 100% fidelity ratings for the initial participants in each intervention. After demonstrating high treatment fidelity, a minimum of 25% of each participant’s sessions receive fidelity ratings by the principal investigator on the same QOLT and HHE Fidelity scales. Feasibility, acceptability, and treatment fidelity will be evaluated not only between intervention groups but also across mode of intervention delivery (in-person and phone).

Outcomes

Analyses

Statistical analyses have been developed to support each of the 4 specific aims of the project. Preliminary analyses (Chi-Square tests or analysis of variance [ANOVA]) will first be conducted to examine participant characteristics in the QOLT group versus the HHE group for comparability at baseline on various demographic, cardiovascular history, and psychosocial and behavioral characteristics. If any group differences are found, we will evaluate them and if necessary we will statistically control them in the outcome analyses.

Aim 1 will examine variables that are associated with the feasibility and acceptability of the intervention protocol, at both pre-intervention (recruitment, screening and enrollment process) and post-intervention (attendance, homework completion, attrition, adverse events, participant program evaluation). Some of these analyses are descriptive in nature, such as percent of participants recruited, rate of accrual, total attrition, attrition rate over time, percent accepting randomization to treatment, number of adverse events, and percent compliance with study protocols (measured by number of sessions attended). Study goals are 80% retention of our cohort to denote feasibility, a 75% attendance rate to demarcate delivery of a full versus a partial intervention dosage, and will also use a 75% completion rate of homework assignments in the QOLT group. These analyses will be especially useful in guiding and informing the implementation of the future R01 efficacy trial. To further investigate adherence, we will also conduct 2 linear mixed model longitudinal analyses over

3 monthly time points to examine the number of sessions and homework assignments completed each month, and will employ the intention-to-treat principle using all randomized participants in the analyses.

Aim 2 will estimate the QOLT intervention effect size with respect to arrhythmia frequency versus the effect of the HHE group. This analysis will examine the frequency count of arrhythmias in each participant for the period between the 3-month immediate post-treatment assessment and the 9-month final assessment using a Poisson regression model with a binary treatment group indicator as the predictor. We will perform a second analysis on the frequency counts during the period between baseline and the 3-month immediate post-treatment assessment to examine for early treatment effects. These analyses will employ the intention-to-treat principle to calculate treatment effects and differences using all randomized participants. Additional covariates may be included in these analyses, if the preliminary analyses indicate the need for statistical control. Additional Poisson modeling analyses will also examine the frequency count of ICD therapies (alone and combined with arrhythmia frequency) to provide a richer examination of the mechanistic and electrophysiological profile of the participants and the effects of the interventions.

Aim 3 will examine psychological improvement in well-being and QOL from baseline to 3-, and 9- month assessment for QOLT versus HHE. An initial analysis of covariance (ANCOVA), using baseline measures of well-being and QOL as covariates, will examine change from baseline to the 3-month immediate post-treatment follow-up. A second longitudinal linear mixed model analysis (baseline, 3-, 9-month) will examine for extended treatment effects and will compare within group trends over time. If indicated by preliminary analyses, additional covariates may be included in these analyses.

Aim 4 will estimate the QOLT intervention effects with respect to autonomic function as measured by HRV and HRT, and the differential effect for autonomic function when compared to the effects of the HHE group. Our primary HRV variable of interest is the HF-HRV, indicative of parasympathetic activity. Separate ANCOVAs will be conducted for each dependent variable, using baseline measurements of HRV and HRT as covariates, to examine change from baseline to the 3-month assessment. A second longitudinal linear mixed model analysis (baseline, 3-, 9-month) will also be conducted to examine for extended treatment effects and to compare within group trends over time, with additional covariates included, if necessary, in these analyses.

DISCUSSION

Reducing arrhythmias via a non-invasive, non-pharmacologic method that is also designed to improve well-being has tremendous potential benefit to the individual and to public health as a whole. Improving mental and physical health of ICD patients is critical because: (1) this group is at high risk for ventricular arrhythmias and sudden death, (2) depressed or anxious CHD patients appear to be at even higher risk for mortality compared to non-depressed or non-anxious CHD patients,^{104,105} and (3) negative emotions and arrhythmias form a downward spiral further worsening mood, well-being, and cardiovascular health.^{106,107} Unique to ICD patients is the ability to objectively and quantifiably measure arrhythmic

events by the ICD, providing optimal measurement of arrhythmias. We hypothesize that a positive-emotion focused cognitive behavior therapy (i.e., Quality of Life Therapy [QOLT]) will reduce arrhythmias. Much research demonstrates that positive emotion is related to health benefits, physiology, and increased survival.^{20,21,24,25,29,41–44}

This pilot RCT is testing the feasibility and acceptability of a manualized positive-emotion focused cognitive behavioral therapy treatment program using QOLT for ICD patients. Additionally, the pilot study will examine the effects of this positive psychotherapy intervention on ventricular arrhythmias, autonomic functioning, and mood in ICD patients with left ventricular dysfunction. *Innovative aspects* of this trial include: (1) a focus on positive emotion and using a strength-based intervention focused on increasing quality of life; (2) the use of several measures of autonomic function in attempt to capture different aspects of sympathetic and parasympathetic functioning; (3) an attempt to count frequency of arrhythmias and ICD therapies, rather than only examining time to first event. This trial makes use of the already-existing technology within ICDs to obtain primary outcome data. The effect size estimates obtained in this study will be used to inform the design of a rigorous efficacy trial of QOLT among ICD patients to test whether QOLT can reduce arrhythmias.

This study has both theoretical and clinical impact. The *theoretical significance* of this trial lies in testing the mechanistic pathway by which QOLT acts on arrhythmias (i.e., autonomic function). This will enable us to design non-pharmacologic, non-invasive treatments to reduce arrhythmias (and thereby, shocks). The *clinical significance* of the trial is that patients are receiving immediate intervention which is promoting mood and life satisfaction. Currently with anecdotal evidence only, participants are reporting tremendous positive benefit. In addition, improvements in QOL and psychological well-being may have both direct and indirect effects on physical and mental health, and may be further examined in a larger, fully-powered R01 in the future.

Data from this study has the potential to provide important feasibility and pilot information to be used as the foundation for a larger trial. It may enable us to introduce a better standard of care for ICD patients, improving well-being and reducing emotion-triggered arrhythmias and ICD shocks. It may also aid in the identification of behavioral therapies that may be beneficial for patients who may be prone to emotion-triggered arrhythmias, allowing for better stratification for treatments. For example, if there is benefit, or even a demonstration of a positive effect size for the QOLT group and enhanced positive wellbeing on autonomic function or arrhythmia frequency, then positive psychotherapy may be worth considering as a standard adjuvant treatment to help reduce arrhythmias, improve cardiovascular function, quality of life, and positive wellbeing.

In sum, the present trial provides a novel approach to examining relationships between positive emotion, autonomic functioning, and heart functioning. This study also makes important strides towards examining the role of positive psychology interventions and physical health outcomes. This is the first trial, to our knowledge, examining the role of a positive psychology intervention in ICD patients, and has the potential to improve care for these patients.

Acknowledgments

Funding: National Institutes of Health, National Heart, Lung, and Blood Institute (R34 107733)

I need to wholeheartedly thank all of the clinic and nursing staff who have helped us recruit participants from the clinics. Tammy Gottshalk, FNP and Peter Bearden, RN have been champions for the study. Furthermore, all of the research assistants who have screened countless patients to be participants: Jkeonye Moss, Brandon Payton, Sarah Hamilton, and Annabel Franz.

References

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. Feb 14; 2006 113(6):e85–151. [PubMed: 16407573]
2. Stanley, Morgan. Hospital Supplies and Technology First Quarter 2006. 2006. Equity Research North America.
3. Wurster, C. [Accessed September, 2015] Published in the online edition of Heart Rhythm this month the updated Registry includes more than 850,000 ICD procedures from more than 1,400 institutions. 2013. <http://www.hrsonline.org/News/Press-Releases/20132/03/ICD-Registry-Update#axzz3m7ShHJM>
4. Magyar-Russell G, Thombs BD, Cai JX, Baveja T, Kuhl EA, Singh PP, Barroso MMB, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: A systematic review. *Journal of psychosomatic research*. 2011; 71:223–231. [PubMed: 21911099]
5. Sears SE Jr, Conti JB. Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research and clinical care. *Clin Cardiol*. Mar; 2003 26(3):107–111. [PubMed: 12685615]
6. Bilge AK, Ozben B, Demircan S, Cinar M, Yilmaz E, Adalet K. Depression and anxiety status of patients with implantable cardioverter defibrillator and precipitating factors. *Pacing Clin Electrophysiol*. Jun; 2006 29(6):619–626. [PubMed: 16784428]
7. Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, Capone RJ, et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). *Am J Cardiol*. Jul 1; 1990 66(1):59–62. [PubMed: 2193497]
8. Ziegelstein RC. Acute emotional stress and cardiac arrhythmias. *JAMA*. Jul 18; 2007 298(3):324–329. [PubMed: 17635893]
9. Dunbar SB, Kimble LP, Jenkins LS, Hawthorne M, Dudley W, Slemmons M, Langberg JJ. Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. *Depress Anxiety*. 1999; 9(4):163–168. [PubMed: 10431681]
10. Lampert R, Joska T, Burg MM, Batsford WP, McPherson CA, Jain D. Emotional and physical precipitants of ventricular arrhythmia. *Circulation*. Oct 1; 2002 106(14):1800–1805. [PubMed: 12356633]
11. Shedd OL, Sears SF Jr, Harvill JL, Arshad A, Conti JB, Steinberg JS, Curtis AB. The World Trade Center attack: increased frequency of defibrillator shocks for ventricular arrhythmias in patients living remotely from New York City. *J Am Coll Cardiol*. Sep 15; 2004 44(6):1265–1267. [PubMed: 15364330]
12. Lampert R, Shusterman V, Burg M, McPherson C, Batsford W, Goldberg A, Soufer R. Anger-induced T-wave alternans predicts future ventricular arrhythmias in patients with implantable cardioverter-defibrillators. *J Am Coll Cardiol*. Mar 3; 2009 53(9):774–778. [PubMed: 19245968]
13. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. *J Am Coll Cardiol*. Mar 1; 2005 45(5):637–651. [PubMed: 15734605]
14. Lown B, Verrier R, Corbalan R. Psychologic stress and threshold for repetitive ventricular response. *Science*. Nov 23; 1973 182(114):834–836. [PubMed: 4795748]

15. Carney RM, Freedland KE, Stein PK, Miller GE, Steinmeyer B, Rich MW, Duntley SP. Heart rate variability and markers of inflammation and coagulation in depressed patients with coronary heart disease. *Journal of psychosomatic research*. Apr; 2007 62(4):463–467. [PubMed: 17383498]
16. Davydov DM, Shapiro D, Cook IA, Goldstein I. Baroreflex mechanisms in major depression. *Prog Neuropsychopharmacol Biol Psychiatry*. Jan 30; 2007 31(1):164–177. [PubMed: 17011098]
17. Lane RD, Reis HT, Peterson DR, Zareba W, Moss AJ. Happiness and stress alter susceptibility to cardiac events in Long QT Syndrome. *Annals of noninvasive electrocardiology: the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.* Apr; 2009 14(2): 193–200.
18. Ong AD, Allaire JC. Cardiovascular intraindividual variability in later life: the influence of social connectedness and positive emotions. *Psychol Aging*. Sep; 2005 20(3):476–485. [PubMed: 16248706]
19. Bower J, Low C, Moskowitz J, Sepah S, Epel E. Benefit finding and physical health: Positive psychological changes and enhances allostasis. *Social and Personality Psychology Compass*. 2008; 2:223–244.
20. Kubzansky LD, Sparrow D, Vokonas P, Kawachi I. Is the glass half empty or half full? A prospective study of optimism and coronary heart disease in the normative aging study. *Psychosom Med*. Nov-Dec;2001 63(6):910–916. [PubMed: 11719629]
21. Boehm JK, Kubzansky LD. The heart's content: The association between positive psychological well-being and cardiovascular health. *Psychol Bull*. Jul; 2012 138(4):655–691. [PubMed: 22506752]
22. Tindle HA, Chang YF, Kuller LH, Manson JE, Robinson JG, Rosal MC, Siegle GJ, et al. Optimism, cynical hostility, and incident coronary heart disease and mortality in the Women's Health Initiative. *Circulation*. Aug 25; 2009 120(8):656–662. [PubMed: 19667234]
23. Giltay EJ, Kamphuis MH, Kalmijn S, Zitman FG, Kromhout D. Dispositional optimism and the risk of cardiovascular death: the Zutphen Elderly Study. *Arch Intern Med*. Feb 27; 2006 166(4): 431–436. [PubMed: 16505263]
24. Chida Y, Steptoe A. Positive psychological well-being and mortality: a quantitative review of prospective observational studies. *Psychosom Med*. Sep; 2008 70(7):741–756. [PubMed: 18725425]
25. Scheier MF, Matthews KA, Owens JF, Magovern GJ Sr, Lefebvre RC, Abbott RA, Carver CS. Dispositional optimism and recovery from coronary artery bypass surgery: the beneficial effects on physical and psychological well-being. *J Pers Soc Psychol*. Dec; 1989 57(6):1024–1040. [PubMed: 2614656]
26. Scheier MF, Matthews KA, Owens JF, Schulz R, Bridges MW, Magovern GJ, Carver CS. Optimism and rehospitalization after coronary artery bypass graft surgery. *Arch Intern Med*. Apr 26; 1999 159(8):829–835. [PubMed: 10219928]
27. Middleton RA, Byrd EK. Psychosocial factors and hospital readmission status of older persons with cardiovascular disease. *Journal of Applied Rehabilitation Counseling*. 1996; 27:3–10.
28. Barefoot JC, Brummett BH, Williams RB, Siegler IC, Helms MJ, Boyle SH, Clapp-Channing NE, et al. Recovery expectations and long-term prognosis of patients with coronary heart disease. *Arch Intern Med*. May 23; 2011 171(10):929–935. [PubMed: 21357800]
29. Sears SF, Serber ER, Lewis TS, Walker RL, Connors N, Lee JT, Curtis AB, et al. Do positive health expectations and optimism relate to quality-of-life outcomes for the patient with an implantable cardioverter defibrillator? *J Cardiopulm Rehabil*. Sep-Oct;2004 24(5):324–331. [PubMed: 15602153]
30. Steptoe A, Dockray S, Wardle J. Positive affect and psychobiological processes relevant to health. *J Pers*. Dec; 2009 77(6):1747–1776. [PubMed: 19796062]
31. Ramachandruni S, Fillingim RB, McGorray SP, Schmalfuss CM, Cooper GR, Schofield RS, Sheps DS. Mental stress provokes ischemia in coronary artery disease subjects without exercise- or adenosine-induced ischemia. *J Am Coll Cardiol*. Mar 7; 2006 47(5):987–991. [PubMed: 16516082]
32. Billman GE. Aerobic exercise conditioning: a nonpharmacological antiarrhythmic intervention. *J Appl Physiol*. Feb; 2002 92(2):446–454. [PubMed: 11796650]

33. Billman GE, Kukielka M. Effects of endurance exercise training on heart rate variability and susceptibility to sudden cardiac death: protection is not due to enhanced cardiac vagal regulation. *J Appl Physiol*. Mar; 2006 100(3):896–906. [PubMed: 16322370]
34. Rechlin T, Weis M, Spitzer A, Kaschka WP. Are affective disorders associated with alterations of heart rate variability? *J Affect Disord*. Dec; 1994 32(4):271–275. [PubMed: 7897091]
35. Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Waugh R, Georgiades A, Bacon SL, et al. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. *Jama*. Apr 6; 2005 293(13):1626–1634. [PubMed: 15811982]
36. Carney RM, Freedland KE, Stein PK, Skala JA, Hoffman P, Jaffe AS. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. *Psychosom Med*. Sep-Oct;2000 62(5):639–647. [PubMed: 11020093]
37. Chevalier P, Cottraux J, Mollard E, Sai N, Brun S, Burri H, Restier L, et al. Prevention of implantable defibrillator shocks by cognitive behavioral therapy: a pilot trial. *Am Heart J*. Jan. 2006 151(1):191. [PubMed: 16368316]
38. Kohn CS, Petrucci RJ, Baessler C, Soto DM, Movsowitz C. The effect of psychological intervention on patients' long-term adjustment to the ICD: a prospective study. *Pacing Clin Electrophysiol*. Apr; 2000 23(4 Pt 1):450–456. [PubMed: 10793433]
39. Fredrickson BL, Levenson RW. Positive emotions speed recovery from the cardiovascular sequelae of negative emotions. *Cognition and Emotion*. 1998; 12:191–220. [PubMed: 21852890]
40. Fredrickson BL. The role of positive emotions in positive psychology. The broaden-and-build theory of positive emotions. *Am Psychol*. Mar; 2001 56(3):218–226. [PubMed: 11315248]
41. Brummett BH, Helms MJ, Dahlstrom WG, Siegler IC. Prediction of all-cause mortality by the Minnesota Multiphasic Personality Inventory Optimism-Pessimism Scale scores: study of a college sample during a 40-year follow-up period. *Mayo Clin Proc*. Dec; 2006 81(12):1541–1544. [PubMed: 17165632]
42. Maruta T, Colligan RC, Malinchoc M, Offord KP. Optimism-pessimism assessed in the 1960s and self-reported health status 30 years later. *Mayo Clin Proc*. Aug; 2002 77(8):748–753. [PubMed: 12173709]
43. Pressman SD, Cohen S. Does positive affect influence health? *Psychol Bull*. Nov; 2005 131(6): 925–971. [PubMed: 16351329]
44. Rashid T. Positive interventions in clinical practice. *J Clin Psychol*. May; 2009 65(5):461–466. [PubMed: 19294745]
45. Rodrigue JR, Baz MA, Widows MR, Ehlers SL. A randomized evaluation of quality-of-life therapy with patients awaiting lung transplantation. *Am J Transplant*. Oct; 2005 5(10):2425–2432. [PubMed: 16162191]
46. Frisch, M. *Quality of Life Therapy; Applying a Life Satisfaction Approach to Positive Psychology and Cognitive Therapy*. Hoboken, NJ: John Wiley & Sons, Inc; 2006.
47. Biswas-Diener, R.; Dean, B. *Positive Psychology Coaching: Putting the Science of Happiness to Work for Your Clients*. Hoboken, NJ: John Wiley & Sons, Inc; 2007.
48. Rodrigue JR, Widows MR, Baz MA. Caregivers of lung transplant candidates: do they benefit when the patient is receiving psychological services? *Prog Transplant*. Dec; 2006 16(4):336–342. [PubMed: 17183941]
49. Donahue RG, Lampert R, Dornelas E, Clemow L, Burg MM. Rationale and design of a randomized clinical trial comparing stress reduction treatment to usual cardiac care: the Reducing Vulnerability to Implantable Cardioverter Defibrillator Shock-Treated Ventricular Arrhythmias (RISTA) trial. *Psychosom Med*. Feb; 2010 72(2):172–177. [PubMed: 20028832]
50. Salmoirago-Blotcher E, Ockene IS. Methodological limitations of psychosocial interventions in patients with an implantable cardioverter-defibrillator (ICD) A systematic review. *BMC Cardiovasc Disord*. 2009; 9:56. [PubMed: 20040100]
51. Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. *Circulation*. Aug 14; 2001 104(7):796–801. [PubMed: 11502705]

52. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. *J Am Coll Cardiol.* Aug 12; 2008 52(7):541–550. [PubMed: 18687248]
53. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. *J Am Coll Cardiol.* Jul 18; 2006 48(2): 330–339. [PubMed: 16843184]
54. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* Jun; 1983 67(6):361–370. [PubMed: 6880820]
55. Hallas CN, Burke JL, White DG, Connelly DT. A prospective 1-year study of changes in neuropsychological functioning after implantable cardioverter-defibrillator surgery. *Circ Arrhythm Electrophysiol.* Apr; 2010 3(2):170–177. [PubMed: 20197542]
56. Jacq F, Foulldrin G, Savoure A, Anselme F, Baguelin-Pinaud A, Cribier A, Thibaut F. A comparison of anxiety, depression and quality of life between device shock and nonshock groups in implantable cardioverter defibrillator recipients. *Gen Hosp Psychiatry.* May-Jun;2009 31(3): 266–273. [PubMed: 19410106]
57. Kapa S, Rotondi-Trevisan D, Mariano Z, Aves T, Irvine J, Dorian P, Hayes DL. Psychopathology in patients with ICDs over time: results of a prospective study. *Pacing Clin Electrophysiol.* Feb; 2010 33(2):198–208. [PubMed: 19930108]
58. Aben I, Verhey F, Lousberg R, Lodder J, Honig A. Validity of the beck depression inventory, hospital anxiety and depression scale, SCL-90, and hamilton depression rating scale as screening instruments for depression in stroke patients. *Psychosomatics.* Sep-Oct;2002 43(5):386–393. [PubMed: 12297607]
59. Haworth JE, Moniz-Cook E, Clark AL, Wang M, Cleland JG. An evaluation of two self-report screening measures for mood in an out-patient chronic heart failure population. *Int J Geriatr Psychiatry.* Nov; 2007 22(11):1147–1153. [PubMed: 17457953]
60. Grant GM, Salcedo V, Hynan LS, Frisch MB, Puster K. Effectiveness of quality of life therapy for depression. *Psychol Rep.* Jun; 1995 76(3 Pt 2):1203–1208. [PubMed: 7480486]
61. Diener ENW, Harter J, Arora. Wealth and happiness across the world: Material prosperity predicts life evaluation, while psychosocial prosperity predicts positive feeling. *J Pers Soc Psychol.* In press.
62. Burton NW, Pakenham KI, Brown WJ. Evaluating the effectiveness of psychosocial resilience training for heart health, and the added value of promoting physical activity: a cluster randomized trial of the READY program. *BMC Public Health.* 2009; 9:427. [PubMed: 19930615]
63. Rodrigue JR, Mandelbrot DA, Pavlakis M. A psychological intervention to improve quality of life and reduce psychological distress in adults awaiting kidney transplantation. *Nephrol Dial Transplant.* Feb; 2011 26(2):709–715. [PubMed: 20603243]
64. Rodrigue, MD., JR; Pavlakis, M. The quality of life and psychosocial functioning of adults awaiting kidney transplantation can be enhanced with a brief positive psychology intervention. Paper presented at: American Transplant Congress; 2010; San Diego, CA.
65. Abedi MR, Vostanis P. Evaluation of quality of life therapy for parents of children with obsessive-compulsive disorders in Iran. *Eur Child Adolesc Psychiatry.* Feb 16; 2010 19(7):605–613. [PubMed: 20157835]
66. Witkiewitz K, Marlatt GA. Relapse prevention for alcohol and drug problems: that was Zen, this is Tao. *Am Psychol.* May-Jun;2004 59(4):224–235. [PubMed: 15149263]
67. Marcus BH, King TK, Albrecht AE, Parisi AF, Abrams DB. Rationale, design, and baseline data for Commit to Quit: an exercise efficacy trial for smoking cessation among women. *Preventive medicine.* Jul-Aug;1997 26(4):586–597. [PubMed: 9245683]
68. Marcus BH, Lewis BA, Hogan J, King TK, Albrecht AE, Bock B, Parisi AF, et al. The efficacy of moderate-intensity exercise as an aid for smoking cessation in women: a randomized controlled trial. *Nicotine Tob Res.* Dec; 2005 7(6):871–880. [PubMed: 16298722]
69. Bansch D, Bocker D, Brunn J, Weber M, Breithardt G, Block M. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and

implantable cardioverter defibrillators. *J Am Coll Cardiol.* Aug; 2000 36(2):566–573. [PubMed: 10933373]

70. Dichtl W, Wolber T, Paoli U, Brullmann S, Stuhlinger M, Berger T, Spuller K, et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. *Clin Cardiol.* Jul; 2011 34(7):433–436. [PubMed: 21678454]
71. Dorian P. Counterpoint: Implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias increase mortality. *Heart Rhythm.* Jul.2012 9(7):1158. [PubMed: 22120129]
72. Sweeney MO. Point: Implantable cardioverter-defibrillator shocks for ventricular tachyarrhythmias increase mortality. *Heart Rhythm.* Jun; 2012 9(6):985–987. [PubMed: 22120131]
73. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med.* Jan 20; 2005 352(3):225–237. [PubMed: 15659722]
74. Denes P, Gillis AM, Pawitan Y, Kammerling JM, Wilhelmsen L, Salerno DM. Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. *Am J Cardiol.* Oct 1; 1991 68(9):887–896. [PubMed: 1718158]
75. Jose AD, Taylor RR. Autonomic blockade by propranolol and atropine to study intrinsic myocardial function in man. *J Clin Invest.* Nov; 1969 48(11):2019–2031. [PubMed: 5398888]
76. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. *J Am Coll Cardiol.* May 6; 2008 51(18):1725–1733. [PubMed: 18452777]
77. Bauer A, Malik M, Schmidt G, Barthel P, Bonnemeier H, Cygankiewicz I, Guzik P, et al. Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus. *J Am Coll Cardiol.* Oct 21; 2008 52(17):1353–1365. [PubMed: 18940523]
78. Verrier RL, Ikeda T. Ambulatory ECG-based T-wave alternans monitoring for risk assessment and guiding medical therapy: mechanisms and clinical applications. *Prog Cardiovasc Dis.* Sep-Oct; 2013 56(2):172–185. [PubMed: 24215749]
79. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *Circulation.* Mar 1; 1996 93(5):1043–1065. [PubMed: 8598068]
80. Goedhart AD, van der Sluis S, Houtveen JH, Willemsen G, de Geus EJ. Comparison of time and frequency domain measures of RSA in ambulatory recordings. *Psychophysiology.* Mar; 2007 44(2):203–215. [PubMed: 17343704]
81. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. *Science.* Jul 10; 1981 213(4504):220–222. [PubMed: 6166045]
82. Lane RD, McRae K, Reiman EM, Chen K, Ahern GL, Thayer JF. Neural correlates of heart rate variability during emotion. *Neuroimage.* Jan 1; 2009 44(1):213–222. [PubMed: 18778779]
83. McCraty R, Atkinson M, Tiller WA, Rein G, Watkins AD. The effects of emotions on short-term power spectrum analysis of heart rate variability. *Am J Cardiol.* Nov 15; 1995 76(14):1089–1093. [PubMed: 7484873]
84. Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, Camm AJ, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. *Lancet.* Apr 24; 1999 353(9162):1390–1396. [PubMed: 10227219]
85. La Rovere MT, Mortara A, Schwartz PJ. Baroreflex sensitivity. *J Cardiovasc Electrophysiol.* Sep; 1995 6(9):761–774. [PubMed: 8556196]
86. Analyses WGoBS. Heart Rate Turbulence. <http://www.h-r-t.org/hrt/en/calc.html>
87. Iwasa A, Hwa M, Hassankhani A, Liu T, Narayan SM. Abnormal heart rate turbulence predicts the initiation of ventricular arrhythmias. *Pacing Clin Electrophysiol.* Nov; 2005 28(11):1189–1197. [PubMed: 16359285]

88. Cygankiewicz I, Wranicz JK, Bolinska H, Zaslonka J, Zareba W. Relationship between heart rate turbulence and heart rate, heart rate variability, and number of ventricular premature beats in coronary patients. *J Cardiovasc Electrophysiol*. Jul; 2004 15(7):731–737. [PubMed: 15250853]
89. Verrier RL, Klingenhoben T, Malik M, El-Sherif N, Exner DV, Hohnloser SH, Ikeda T, et al. Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility--consensus guideline by International Society for Holter and Noninvasive Electrocardiology. *J Am Coll Cardiol*. Sep 20; 2011 58(13):1309–1324. [PubMed: 21920259]
90. Pedersen SS, Theuns DA, Erdman RA, Jordaens L. Clustering of device-related concerns and type D personality predicts increased distress in ICD patients independent of shocks. *Pacing Clin Electrophysiol*. Jan; 2008 31(1):20–27. [PubMed: 18181906]
91. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *Journal of psychosomatic research*. Feb; 2002 52(2):69–77. [PubMed: 11832252]
92. Kuhl EA, Dixit NK, Walker RL, Conti JB, Sears SF. Measurement of patient fears about implantable cardioverter defibrillator shock: an initial evaluation of the Florida Shock Anxiety Scale. *Pacing Clin Electrophysiol*. Jun; 2006 29(6):614–618. [PubMed: 16784427]
93. Burns JL, Serber ER, Keim S, Sears SF. Measuring patient acceptance of implantable cardiac device therapy: initial psychometric investigation of the Florida Patient Acceptance Survey. *J Cardiovasc Electrophysiol*. Apr; 2005 16(4):384–390. [PubMed: 15828880]
94. Fordyce M. A review of research on the Happiness Measures: A sixty second index of happiness and mental health. *Social Indicators Research*. 1988; 20(4):355–381.
95. Diener E. Subjective well-being. *Psychol Bull*. May; 1984 95(3):542–575. [PubMed: 6399758]
96. Radloff LS. The CES-D Scale: A self-report depression scale for research in the general population. *Applied Psychological Measurement*. 1977; 1(3):285–401.
97. Spielberger, C.; Gorsuch, R.; Lushene, R.; Vagg, P.; Jacobs, G. Manual for the State-Trait Anxiety Inventory (Self Evaluation Questionnaire: Form Y). Palo Alto: Consulting Psychologist Press, Inc; 1983.
98. Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. *J Pers Soc Psychol*. Dec; 1994 67(6):1063–1078. [PubMed: 7815302]
99. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol*. Jun; 1988 54(6):1063–1070. [PubMed: 3397865]
100. Diener E, Emmons RA, Larsen RJ, Griffin S. The Satisfaction With Life Scale. *J Pers Assess*. Feb; 1985 49(1):71–75. [PubMed: 16367493]
101. Frisch, MB. Manual and Treatment Guide for the Quality of Life Inventory or QOLI®. Minneapolis, MN: Pearson Assessments (formerly, National Computer Systems); 1994.
102. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. Jun; 1992 30(6):473–483. [PubMed: 1593914]
103. Rector T, Kubo S, Cohn J. Patients' assessment of their congestive heart failure: Vol. 2. Content, reliability, and validity of a new measure—The Minnesota Living with Heart Failure Questionnaire. *Heart Fail*. 1987; 3:198–209.
104. Damen NL, Pelle AJ, Boersma E, Serruys PW, van Domburg RT, Pedersen SS. Reduced positive affect (anhedonia) is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention: results from the RESEARCH registry. *Eur J Prev Cardiol*. Jan 16.2012
105. Frasure-Smith N, Lesperance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. *Arch Gen Psychiatry*. Jan; 2008 65(1):62–71. [PubMed: 18180430]
106. Cevik CP-V, Alejandro, Nugent Kenneth. Implantable cardioverter defibrillators and their role in heart failure progress. *Europace*. Jun.2009 11(6):6.
107. Steinberg JS, Joshi S, Schron EB, Powell J, Hallstrom A, McBurnie M. Psychosocial status predicts mortality in patients with life-threatening ventricular arrhythmias. *Heart Rhythm*. Mar; 2008 5(3):361–365. [PubMed: 18313592]

Table 1

Schedule of study measures

Measure	Baseline	Weekly 0–3 mo	3-month	6-month	9-month
Hospital Anxiety and Depression Scale (HADS)	Screener			✓	
Demographics	✓				
Medical History	✓				
ICD History	✓				
Psychosocial History	✓				
Intervention Process Measures		✓	✓		
Clinical Electrophysiologic Variables	✓		✓	✓	✓
Psychological Well-being Measures	✓		✓		✓
Quality of Life Measures	✓		✓		✓
Heart Rate Variability	✓		✓		✓